SCHEDULE: BlackRock Discloses 5.8% Stake in Abeona Therapeutics

Sentiment:

Beneficial Ownership Report 17 July 2025 7:44 PM

BlackRock, Inc. has reported a 5.8% beneficial ownership stake in Abeona Therapeutics Inc. common stock as of June 30, 2025, held in the ordinary course of business.

Summary

BlackRock, Inc. reported beneficial ownership of 2,949,262 shares of Abeona Therapeutics Inc. common stock.
This represents 5.8% of the outstanding common stock of Abeona Therapeutics Inc.
BlackRock holds sole voting power over 2,909,456 shares and sole dispositive power over 2,949,262 shares.
The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
The filing date for the event was June 30, 2025.
BlackRock, Inc. is classified as a parent holding company.
Several BlackRock subsidiaries, including BlackRock Advisors, LLC, BlackRock Fund Advisors, BlackRock Institutional Trust Company, National Association, BlackRock Financial Management, Inc., and BlackRock Investment Management, LLC, are involved in the beneficial ownership, with some entities beneficially owning 5% or greater of the outstanding shares.

Sentiment

Score: 7

Explanation: The filing itself is neutral as a regulatory disclosure. However, a significant stake by a major institutional investor like BlackRock can be perceived positively by the market as a vote of confidence, assuming the investment is passive and in the ordinary course of business, as stated.

Positives

A major institutional investor like BlackRock holding a significant stake can be seen as a vote of confidence in the company's long-term prospects.
The filing explicitly states that the shares are held in the ordinary course of business and not for the purpose of changing or influencing control, indicating a passive investment.

Future Outlook

This Schedule 13G filing reports current beneficial ownership and does not contain any forward-looking statements or guidance regarding Abeona Therapeutics Inc.'s future performance or strategic outlook.

Management Comments

The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.

Industry Context

This filing indicates a significant passive investment by a major asset manager in a biotechnology company. Such investments are common and reflect institutional confidence in the sector or specific company, but do not imply strategic involvement or operational changes.

Comparison to Industry Standards

BlackRock's 5.8% stake in Abeona Therapeutics is a standard disclosure for institutional investors crossing the 5% beneficial ownership threshold, as required by SEC regulations.
This type of passive investment by large asset managers like BlackRock is common across various industries, including biotechnology, where they often hold diversified portfolios.
The document does not provide specific comparable companies, projects, or financial results for Abeona Therapeutics to assess its performance against industry standards; it solely focuses on BlackRock's ownership.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Internal Corporate Governance (BlackRock, Inc.)	BlackRock, Inc. updated its Power of Attorney, effective January 21, 2025, which authorizes specific individuals to execute SEC filings on its behalf and on behalf of its direct and indirect subsidiaries and affiliates. This new power of attorney revokes a previous one dated April 30, 2023.	2025-01-21	This change streamlines BlackRock's internal process for compliance with ownership and control-person reporting requirements, ensuring authorized personnel can efficiently file necessary documents with regulatory authorities. It does not directly impact Abeona Therapeutics Inc.'s corporate governance.

Stakeholder Impact

Shareholders: May view BlackRock's significant stake as a positive signal of institutional confidence in Abeona Therapeutics.
Management: Awareness of a major institutional holder, but no direct impact on operations or strategy is implied by a passive 13G filing.

Key Dates

Date	Description
2023-04-30	Previous Power of Attorney for BlackRock, Inc. was dated and subsequently revoked.
2025-01-21	Effective date of the new Power of Attorney for BlackRock, Inc.
2025-06-30	Date of event which required the filing of this statement (beneficial ownership threshold crossed/reported).
2025-07-17	Date of filing signature by Spencer Fleming, Managing Director of BlackRock, Inc.

Recommendation

hold

Keywords

Abeona Therapeutics Inc., BlackRock Inc., Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Biotechnology

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.